Application of cytogenetics in neoplastic diseases.
This review will concern itself with the application of cytogenetic findings in neoplastic diseases. This application can be divided into two general categories: practical and theoretical. The practical applications reside in utilizing karyotypic changes, particularly in leukemias and lymphomas, not only for diagnostic purposes but also for predicting response to therapy and prognosis. This is especially evident in the various acute nonlymphocytic leukemias and in most of the acute lymphoblastic leukemias. Thus, a definite correlation exists between the cytogenetic findings and the various clinical, laboratory, and cytologic parameters of most of the leukemias. Undoubtedly, these leukemias will ultimately be classified and defined more in terms of their cytogenetic aspects than any other. Though the application in lymphoma is not at the same level as that in leukemia, developments in that field certainly indicate a similar utilization of the cytogenetic findings in these diseases. The presence or absence of a Ph1 chromosome in a chronic myelocytic leukemia has been utilized widely, not only in the diagnosis but also in the predictability of response; the cytogenetic findings have also been utilized in predicting the blastic phase of disease. The list of specific chromosome changes in various solid tumors is of a lesser number, but significant developments indicate that the applicability of chromosome changes in these diseases will, also, be established in the near future. The application of chromosome findings to theoretical aspects of malignancy has assumed an important place recently in the demonstration that so-called oncogenes (or proto-oncogenes) are located or associated with areas of human chromosomes in which breaks and translocations are involved. Thus, it appears that chromosome changes in human malignancy, once their specificity is established, are important parameters in the clinical and theoretical aspects of the disease. A discussion will also be given on primary vs. secondary chromosome changes and their significance in the biology and behavior of the malignancy.
D002051:Burkitt Lymphoma / Q000235:genetics; D002869:Chromosome Aberrations / Q000235:genetics*; D002871:Chromosome Banding; D025063:Chromosome Disorders; D002873:Chromosome Fragility; D005260:Female; D006570:Heterochromatin / Q000648:ultrastructure; D006689:Hodgkin Disease / Q000235:genetics; D006801:Humans; D007621:Karyotyping; D007938:Leukemia / Q000235:genetics*; D007945:Leukemia, Lymphoid / Q000235:genetics; D007948:Leukemia, Monocytic, Acute / Q000235:genetics; D007951:Leukemia, Myeloid / Q000235:genetics; D015470:Leukemia, Myeloid, Acute / Q000235:genetics; D008223:Lymphoma / Q000235:genetics*; D008297:Male; D009369:Neoplasms / Q000235:genetics*; D009857:Oncogenes; D010677:Philadelphia Chromosome; D011110:Polymorphism, Genetic; D011379:Prognosis; D013601:T-Lymphocytes; D014178:Translocation, Genetic
D006570:Heterochromatin